Langbahn Team – Weltmeisterschaft

MTDH

MTDH
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesMTDH, 3D3, AEG-1, AEG1, LYRIC, LYRIC/3D3, metadherin
External IDsOMIM: 610323; MGI: 1914404; HomoloGene: 12089; GeneCards: MTDH; OMA:MTDH - orthologs
Orthologs
SpeciesHumanMouse
Entrez

92140

67154

Ensembl

ENSG00000147649

ENSMUSG00000022255

UniProt

Q86UE4

Q80WJ7

RefSeq (mRNA)

NM_178812
NM_001363136
NM_001363137
NM_001363138
NM_001363139

NM_026002
NM_001357925
NM_001357926

RefSeq (protein)

NP_848927
NP_001350065
NP_001350066
NP_001350067
NP_001350068

NP_080278
NP_001344854
NP_001344855

Location (UCSC)Chr 8: 97.64 – 97.73 MbChr 15: 34.08 – 34.15 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Metadherin, also known as protein LYRIC or astrocyte elevated gene-1 protein (AEG-1) is a protein that in humans is encoded by the MTDH gene.[5][6][7]

Function

MTDH (AEG-1) is involved in HIF-1alpha mediated angiogenesis. MTDH also interacts with SND1 and involved in RNA-induced silencing complex (RISC) and plays very important role in RISC and miRNA functions.[8][9] MTDH has been shown to interact with spliceosome proteins in the cell nucleus and regulate the process of alternative splicing.[10]

MTDH induces an oncogene called Late SV40 factor (LSF/TFCP2) which is involved in thymidylate synthase (TS) induction and DNA biosynthesis synthesis.[11] Late SV40 factor (LSF/TFCP2) enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP9).[12]

Clinical significance

MTDH acts as an oncogene in melanoma, malignant glioma, breast cancer and hepatocellular carcinoma.[13] It is highly expressed in these cancers and helps in their progression and development. It is induced by c-Myc oncogene and plays an important role in anchorage independent growth of cancer cells (metastasis).

Elevated expression of MTDH, which is overexpressed in more than 40% of breast cancers, is associated with poor clinical outcomes. MTDH has a dual role in promoting metastatic seeding and enhancing chemoresistance. MTDH is therefore a potential therapeutic target for enhancing chemotherapy and reducing metastasis.[14][15][16][17]

MTDH has been shown to be overexpressed in prostate cancer, where there is a shift towards a more cytoplasmic localisation, signalling a poor prognosis.[18][19] In the nucleus of prostate cancer cells, MTDH has been shown to affect alternative splicing of genes such as CD44, which may also be associated with prostate cancer progression.[10]

LSF/TFCP2 plays a multifaceted role in chemo resistance, EMT, allergic response, inflammation and Alzheimer's disease.[20]

MTDH controls many hallmarks of oncogenes and cancer. MTDH/AEG-1 induces hepato steatosis in mouse liver.[21] MTDH knockdown by artificial microRNA interference functions as a potential tumor suppressor in breast cancer.[22] Astrocyte elevated gene-1/MTDH undergoes palmitoylation in normal and abnormal cell physiology.[23] Biomaterial titanium substrata with microgrooves can alter MTDH expression in human primary cells.[24]

Interactions

MTDH has been shown to interact with:

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000147649 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000022255 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ "Entrez Gene: MTDH metadherin".
  6. ^ Brown DM, Ruoslahti E (April 2004). "Metadherin, a cell surface protein in breast tumors that mediates lung metastasis". Cancer Cell. 5 (4): 365–74. doi:10.1016/S1535-6108(04)00079-0. PMID 15093543.
  7. ^ Sutherland HG, Lam YW, Briers S, Lamond AI, Bickmore WA (March 2004). "3D3/lyric: a novel transmembrane protein of the endoplasmic reticulum and nuclear envelope, which is also present in the nucleolus". Experimental Cell Research. 294 (1): 94–105. doi:10.1016/j.yexcr.2003.11.020. PMID 14980505.
  8. ^ Yoo BK, Santhekadur PK, Gredler R, Chen D, Emdad L, Bhutia S, et al. (May 2011). "Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma". Hepatology. 53 (5): 1538–48. doi:10.1002/hep.24216. PMC 3081619. PMID 21520169.
  9. ^ Yoo BK, Emdad L, Lee SG, Su ZZ, Santhekadur P, Chen D, et al. (April 2011). "Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology". Pharmacology & Therapeutics. 130 (1): 1–8. doi:10.1016/j.pharmthera.2011.01.008. PMC 3043119. PMID 21256156.
  10. ^ a b Luxton HJ, Simpson BS, Mills IG, Brindle NR, Ahmed Z, Stavrinides V, Heavey S, Stamm S, Whitaker HC (September 2019). "The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing". Cancers. 11 (9): 1233. doi:10.3390/cancers11091233. PMC 6770463. PMID 31450747.
  11. ^ Yoo BK, Gredler R, Vozhilla N, Su ZZ, Chen D, Forcier T, et al. (August 2009). "Identification of genes conferring resistance to 5-fluorouracil". Proceedings of the National Academy of Sciences of the United States of America. 106 (31): 12938–43. Bibcode:2009PNAS..10612938Y. doi:10.1073/pnas.0901451106. PMC 2722317. PMID 19622726.
  12. ^ Santhekadur PK, Gredler R, Chen D, Siddiq A, Shen XN, Das SK, et al. (January 2012). "Late SV40 factor (LSF) enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP-9)". The Journal of Biological Chemistry. 287 (5): 3425–32. doi:10.1074/jbc.M111.298976. PMC 3270996. PMID 22167195.
  13. ^ Yoo BK, Emdad L, Su ZZ, Villanueva A, Chiang DY, Mukhopadhyay ND, et al. (March 2009). "Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression". The Journal of Clinical Investigation. 119 (3): 465–77. doi:10.1172/JCI36460. PMC 2648696. PMID 19221438.
  14. ^ Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, et al. (January 2009). "MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer". Cancer Cell. 15 (1): 9–20. doi:10.1016/j.ccr.2008.11.013. PMC 2676231. PMID 19111877.
  15. ^ Shen M, Wei Y, Kim H, Wan L, Jiang YZ, Hang X, et al. (2021-11-29). "Small-molecule inhibitors that disrupt the MTDH–SND1 complex suppress breast cancer progression and metastasis". Nature Cancer. 3 (1): 43–59. doi:10.1038/s43018-021-00279-5. ISSN 2662-1347. PMC 8818087. PMID 35121987.
  16. ^ Shen M, Smith HA, Wei Y, Jiang YZ, Zhao S, Wang N, et al. (2021-11-29). "Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer". Nature Cancer. 3 (1): 60–74. doi:10.1038/s43018-021-00280-y. ISSN 2662-1347. PMC 8818088. PMID 35121988.
  17. ^ "New cancer therapy from Yibin Kang's lab holds potential to switch off major cancer types without side effects". Princeton University. Retrieved 2021-12-10.
  18. ^ Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, et al. (December 2007). "Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity". Oncogene. 26 (55): 7647–55. doi:10.1038/sj.onc.1210572. PMID 17563745. S2CID 887427. (Retracted, see doi:10.1038/s41388-022-02501-9, PMID 36261628,  Retraction Watch. If this is an intentional citation to a retracted paper, please replace {{retracted|...}} with {{retracted|...|intentional=yes}}.)
  19. ^ Thirkettle HJ, Girling J, Warren AY, Mills IG, Sahadevan K, Leung H, et al. (May 2009). "LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals". Clinical Cancer Research. 15 (9): 3003–13. doi:10.1158/1078-0432.CCR-08-2046. PMID 19383828.
  20. ^ Santhekadur PK, Rajasekaran D, Siddiq A, Gredler R, Chen D, Schaus SC, Hansen U, Fisher PB, Sarkar D (2012). "The transcription factor LSF: a novel oncogene for hepatocellular carcinoma" (PDF). Am J Cancer Res. 2 (3): 269–285. PMC 3365805. PMID 22679558.
  21. ^ Srivastava J, Siddiq A, Emdad L, Santhekadur PK, Chen D, Gredler R, et al. (November 2012). "Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model". Hepatology. 56 (5): 1782–91. doi:10.1002/hep.25868. PMC 3449036. PMID 22689379.
  22. ^ Wang S, Shu JZ, Cai Y, Bao Z, Liang QM (2012). "Establishment and characterization of MTDH knockdown by artificial MicroRNA interference - functions as a potential tumor suppressor in breast cancer" (PDF). Asian Pacific Journal of Cancer Prevention. 13 (6): 2813–8. doi:10.7314/apjcp.2012.13.6.2813. PMID 22938464.
  23. ^ Martin BR, Wang C, Adibekian A, Tully SE, Cravatt BF (November 2011). "Global profiling of dynamic protein palmitoylation". Nature Methods. 9 (1): 84–9. doi:10.1038/nmeth.1769. PMC 3248616. PMID 22056678.
  24. ^ Lee MH, Kang JH, Lee SW (April 2012). "The significance of differential expression of genes and proteins in human primary cells caused by microgrooved biomaterial substrata". Biomaterials. 33 (11): 3216–34. doi:10.1016/j.biomaterials.2012.01.034. PMID 22285466.
  25. ^ Lee SJ, Choi KM, Bang G, Park SG, Kim EB, Choi JW, et al. (June 2021). "Identification of Nucleolin as a Novel AEG-1-Interacting Protein in Breast Cancer via Interactome Profiling". Cancers. 13 (11): 2842. doi:10.3390/cancers13112842. PMC 8201222. PMID 34200450. S2CID 235436955.
  26. ^ Neeli PK, Gollavilli PN, Mallappa S, Hari SG, Kotamraju S (March 2020). "A novel metadherinΔ7 splice variant enhances triple negative breast cancer aggressiveness by modulating mitochondrial function via NFĸB-SIRT3 axis". Oncogene. 39 (10): 2088–2102. doi:10.1038/s41388-019-1126-6. PMID 31806873. S2CID 208648747.

Further reading

Quelle: http://en.wikipedia.org/wiki/MTDH